Study finds short window for donating convalescent plasma to COVID-19 patients

(Penn State) The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study. The research also reveals that the ideal convalescent plasma donor is a recovered COVID-19 patient who is older than 30 and whose illness had been severe.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news